Prostate Cancer

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Matthew R. Smith, MD, PhD, discussed patient characteristics and disease factors that influence treatment intensification decisions in mHSPC.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.